Promising clinical benefit rates in advanced cancers alongside potential biomarker correlation in a phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy
Bono, P. Pasanen, A. Verlingue, L. de Jonge, M. J. A. de Miguel, M. J. Skytta, T. Iivanainen, S. Shetty, S. Ma, Y. T. Graham, Donna
Bono, P.
Pasanen, A.
Verlingue, L.
de Jonge, M. J. A.
de Miguel, M. J.
Skytta, T.
Iivanainen, S.
Shetty, S.
Ma, Y. T.
Graham, Donna
Citations
Altmetric:
Abstract
Authors
Bono, P.
Pasanen, A.
Verlingue, L.
de Jonge, M. J. A.
de Miguel, M. J.
Skytta, T.
Iivanainen, S.
Shetty, S.
Ma, Y. T.
Graham, Donna
Arora, S. P.
Jaakkola, P.
Yap, C.
Jalkanen, S.
Hollmen, M.
Koivunen, J.
Minchom, A. R.
Pasanen, A.
Verlingue, L.
de Jonge, M. J. A.
de Miguel, M. J.
Skytta, T.
Iivanainen, S.
Shetty, S.
Ma, Y. T.
Graham, Donna
Arora, S. P.
Jaakkola, P.
Yap, C.
Jalkanen, S.
Hollmen, M.
Koivunen, J.
Minchom, A. R.
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Bono P, Pasanen A, Verlingue L, de Jonge MJA, de Miguel MJ, Skytta T, et al. Promising clinical benefit rates in advanced cancers alongside potential biomarker correlation in a phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300868.